MYGN logo

Myriad Genetics Inc. (MYGN)

$5.54

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MYGN

Market cap

$531408966

EPS

-1.37

P/E ratio

--

Price to sales

0.51

Dividend yield

--

Beta

1.627532

Price on MYGN

Previous close

$5.57

Today's open

$5.54

Day's range

$5.42 - $5.71

52 week range

$2.74 - $8.09

Profile about MYGN

CEO

Sam Raha

Employees

2700

Headquarters

Salt Lake City, UT

Exchange

Nasdaq Global Select

Shares outstanding

95922196

Issue type

Common Stock

MYGN industries and sectors

Healthcare

Medical Diagnostics & Screening

News on MYGN

Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth

SALT LAKE CITY, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces an expansion of its collaboration with SRL, one of the Japan's largest and leading clinical laboratory testing companies, to enable local testing for BRACAnalysis® Diagnostic System in Japan, subject to regulatory approval. The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.

news source

GlobeNewsWire • Nov 17, 2026

news preview

Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript

Myriad Genetics, Inc. ( MYGN ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Adam Wieschhaus - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.

news source

Seeking Alpha • Nov 10, 2026

news preview

Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript

Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Third Quarter 2026 Financial Earnings Conference Call.

news source

Seeking Alpha • Nov 5, 2026

news preview

Myriad Genetics Q3 Earnings Call Highlights

Myriad Genetics NASDAQ: MYGN reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal business. The company raised its full-year revenue outlook and said early efforts to address reimbursement denials helped improve revenue per test.

news source

MarketBeat • Nov 4, 2026

news preview

Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives

Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to break-even earnings per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences. The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers. The findings, which will be presented as part of the European Society for Medical Oncology (ESMO) Congress 2026, reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of the unit's inventory upon closing.

news source

Benzinga • Oct 20, 2026

news preview

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.

news source

GlobeNewsWire • Oct 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Myriad Genetics Inc.

Open an M1 investment account to buy and sell Myriad Genetics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MYGN on M1